As an add-on therapy for chronic heart conditions, Trimetazidine is generally applied for adult patients whose symptoms are difficult to manage. This application is indicated for adult patients when symptoms require further management.

The primary therapeutic benefit may assist in the symptomatic relief of episodic chest pressure, tightness, or discomfort, and supports improvement in exercise tolerance in patients with ischemic heart disease. This supportive relief can assist with maintaining functional stability during periods of heightened symptoms.

“This medication is considered relevant when supportive symptom management is appropriate and existing first-line treatments have proven insufficient to control symptoms.”

It is relevant for patients whose symptoms are triggered by physical exertion, contributing to improved day-to-day comfort. The primary indications are associated with the symptomatic treatment of stable angina pectoris and its application in situations where additional symptomatic support is required due to persistent symptoms.

---

Quick Fact: Use for Symptomatic Chest Discomfort

Property	Description
Primary Indication	Symptomatic treatment of stable angina pectoris
Core Benefit	Supports reduction in the frequency and intensity of angina attacks
Use Context	Add-on therapy for inadequately controlled symptoms

---

Who Can and Cannot Use Trimetazidine?

The official eligibility profile for Trimetazidine is determined by governmental health authorities and strictly defines populations for whom the medicine is restricted or prohibited.

Contraindications and Absolute Exclusions

Trimetazidine is absolutely contraindicated (must not be used) in patients with the following conditions:

• Hypersensitivity (allergy) to the active substance or any of its excipients.
• Parkinson disease or other parkinsonian symptoms (such as tremor or rigidity).
• Severe renal impairment (kidney disease, defined as creatinine clearance less than 30 mL/min).

Use Requiring Caution or Restriction

Special caution and/or dose adjustment are required for the following groups due to the risk of increased drug exposure:

• Moderate renal impairment (creatinine clearance between 30 and 60 mL/min). A reduced dose is required.
• Elderly patients (generally those over 75 years of age).

Vulnerable Groups and Age Restrictions

• Children and Adolescents (under 18 years): Use is not recommended as safety and efficacy have not been established in this age group.
• Pregnancy and Breastfeeding: The medicine is not recommended or should be avoided during pregnancy and breastfeeding, as data confirming safety for the fetus or infant are insufficient.

Interactions with other medicines and products

Official regulatory information for Trimetazidine generally states that specific pharmacokinetic drug-drug interactions have not been identified. This conclusion is supported by clinical studies cited in official documents.

Documented Interaction Patterns

Interaction Type	Officially Documented Status/Entities
Pharmacokinetic (PK) Interactions	None Identified: Studies show no effect on the pharmacokinetics of medicines like theophylline, digoxin, or phenazone, indicating no significant inhibition or induction of drug metabolism.
Contraindicated Combinations	None: No other medicinal products are formally classified as contraindicated for co-administration.

Pharmacodynamic and Clinical Cautions

While metabolic interactions are not documented, the drug label highlights a specific pharmacodynamic caution and population-specific considerations related to drug exposure:

• Antihypertensive Agents: A risk of Orthostatic Hypotension or falls may occur, particularly in patients receiving concurrent antihypertensive treatment. This is a labeled caution requiring clinical vigilance.
• Food/Supplements: No interactions with foodstuffs, alcohol, or herbal products are explicitly documented in regulatory prescribing information.

Population-Specific Exposure Notes

Official documents advise caution for populations where systemic exposure to Trimetazidine is expected to increase due to reduced clearance:

• Moderate Renal Impairment: Caution is necessary for patients with a creatinine clearance of 30–60 ml/min.
• Elderly Patients: Caution is advised for patients over 75 years old, as age-related decline in renal function may increase drug exposure.

How Trimetazidine Works

Trimetazidine acts via the modulation of energy metabolism, targeting core pathways of ATP production within the myocardial cell.

Targeting Fatty Acid beta-Oxidation

The drug functions by partially inhibiting the enzyme long-chain 3-ketoacyl-CoA thiolase (3-KAT), which catalyzes the final steps of mitochondrial fatty acid oxidation. Inhibiting this enzyme promotes the utilization of glucose oxidation as the predominant energy source. This metabolic shift results in a higher ATP yield per oxygen molecule consumed, correlating to an increased oxygen efficiency of ATP synthesis within the myocardial cell.

️ Influencing Cellular Responses to Stress

The resulting increase in metabolic efficiency influences subsequent cellular responses to stress. By reducing acidosis and limiting the production of toxic metabolites, Trimetazidine helps to stabilize the function of the mitochondria. This stabilization correlates with a reduced propensity for mitochondrial dysfunction, which may limit the progression of cellular damage.

Affecting Ion Homeostasis

The metabolic balance influences intracellular ion levels. By mitigating acidosis, the drug decreases the driving force for the sodium-hydrogen exchanger (Na^+/H^+ exchanger). This mechanism helps mitigate the rise in intracellular Ca^2+ levels that occurs during low oxygen states. The mitigation of intracellular Ca^2+ rise influences cellular excitability and contractility, thereby affecting cellular homeostasis.

How to Use Trimetazidine: Administration Guidelines

Trimetazidine is prescribed as an oral medication. Clinical practice guidelines note that its role is supportive, intended for long-term use and not for treating acute symptoms like an ongoing angina attack or myocardial infarction.

---

Standard Dosing and Frequency

The standard adult regimen depends on the formulation, which is typically a Modified-Release (MR) tablet (35 mg) or an Immediate-Release (IR) tablet (20 mg).

Formulation	Standard Dose	Daily Frequency	Administration Condition
Modified-Release (35 mg)	One 35 mg tablet	Twice daily	To be taken during meals
Immediate-Release (20 mg)	One 20 mg tablet	Three times a day	To be taken during meals

Essential Administration Instructions

To ensure the sustained effect of the MR formulation, the 35 mg tablets must be swallowed whole. They should not be crushed, chewed, or split. This medicine is also taken during meals for both IR and MR forms.

Treatment Duration and Reassessment

The treatment benefit is subject to formal review: the effect of Trimetazidine should be assessed after three months of use. If no clinical improvement is observed by this point, the medication is typically discontinued.

---

Population-Specific Dose Adjustments

Moderate Renal Impairment: For patients with reduced kidney function (creatinine clearance 30 - 60 ml/min), a dose reduction is applied. The dose for the MR tablet is reduced to one 35 mg tablet once daily (in the morning).

Elderly Patients: Dose adjustments should be considered with caution due to the increased likelihood of reduced kidney function in this age group.

Research evidence / Overview of Studies for Trimetazidine

Evidence for Use in Stable Angina Pectoris

Controlled trials, including randomized controlled trials (RCTs), have been conducted during periods of increased symptom activity to study whether the medicine was associated with specific changes in patients experiencing stable angina episodes. Research efforts typically examined outcomes related to physical discomfort, such as the frequency of angina attacks and how often patients needed to use rescue nitrates. Findings describe patterns observed in the studies regarding reported comfort levels and a patient's functional capacity, which often included total exercise duration.

Evidence for Use in Chronic Heart Failure (HF)

Research was studied for its application in patients with chronic heart failure (HF). This body of evidence primarily includes systematic reviews that analyzed multiple smaller trials. These studies examined outcomes related to systemic or functional imbalance, such as measurements of the heart’s pumping efficiency (e.g., LVEF) and changes in functional status (e.g., NYHA class). However, the findings related to all-cause mortality and cardiovascular events were inconsistent and were often derived from synthesizing many small trials.

Evidence in the Context of Heart Procedures (PCI)

Research was evaluated in patients who underwent percutaneous coronary intervention (PCI). These studies focused on episodes where symptoms become more noticeable, especially the incidence of Major Adverse Cardiac Events (MACE). However, reports from one large, long-term trial described an observation of no difference in the primary MACE composite outcome when compared to standard care alone. Comparative evidence is lacking from large-scale studies to clearly establish whether the medicine is associated with changes in MACE risk over many years.

Long-Term Studies and Follow-Up Duration

Studies research examined patient responses over various defined time intervals, with the longest observation periods extending up to four or five years. The available data regarding whether the medicine changes long-term, prognostic outcomes (like survival) is not yet clear or consistent across all trial settings. Follow-up durations were limited in many key trials, meaning the full durability of any symptomatic pattern beyond a few months is still an area being explored.

Evidence in Special Populations and Comorbidities

Research was evaluated in specific patient groups to determine if evidence patterns differed, including elderly patients and individuals with co-existing conditions like Type 2 Diabetes Mellitus. Data for certain groups remain insufficient for populations like children or pregnant individuals. Research was observed in these special populations, but subgroup findings are uncertain and results apply only to the populations studied.

Common questions about Trimetazidine (FAQ)

Q: How soon after starting Trimetazidine can I expect to notice an improvement in my symptoms?

A: Clinical studies and official product information suggest that symptomatic improvement may be observed in patients. Benefits related to exercise tolerance and angina symptoms have been demonstrated over study durations such as 8 to 12 weeks when Trimetazidine is used alongside existing therapy. It is important to note that individual results can vary.

Q: What happens if I accidentally miss a scheduled dose of Trimetazidine?

A: Official patient information advises against taking a double dose to compensate for a single missed dose. Instead, patients are instructed to resume the treatment regimen by taking only the next scheduled dose at its usual time. Always follow the specific instructions provided on your product's leaflet or by a healthcare professional.

Q: Are there any specific vitamins, foods, or supplements that should be avoided while on this medication?

A: Official regulatory documents do not list specific interactions with common foods, vitamins, or supplements. However, the medicine is instructed to be taken during meals for both its immediate-release and modified-release forms, as specified in the prescribing information to aid administration.

Q: What is the international brand name that is most common for the modified-release tablet?

A: In many countries where the drug is approved, the modified-release formulation of Trimetazidine is frequently marketed under the common international brand name Vastarel MR. This sustained-release format is a design choice that helps reduce the frequency of dosing.

Storage and Protection

Official regulatory documents specify that Trimetazidine tablets must be stored at temperatures not exceeding 30 C to maintain product stability. Some formulations may specify a maximum of 25 C. The product is required to be stored out of the sight and reach of children for safety.

To protect the tablets from environmental factors, the medicine must be kept in its original packaging or outer carton to shield it from both light and moisture. Handling instructions mandate that the modified-release tablets must be swallowed whole and not crushed or chewed, as this alters the drug's intended release.

Disposal Requirements

Unused or expired Trimetazidine must be disposed of in a manner that protects the environment. Regulatory guidance explicitly states that the medicine should not be disposed of via household waste or wastewater (flushing down the toilet). Instead, patients must follow local requirements and are generally instructed to consult their pharmacist for appropriate disposal procedures.